TABLE 1.
Subjects’ characteristics and sex hormones during GnRH antagonist (ganirelix acetate) and estradiol (E2) and E2 + testosterone (E2 + T) administration.
| Control Women (n = 7) |
PCOS Women (n = 7) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | GnRH ant | E2 | E2 + T | Baseline | GnRH ant | E2 | E2 + T | |
| Age (yr) | 25.0 ± 4.6 | 24.3 ± 5.6 | ||||||
| Height (cm) | 160.7 ± 5.6 | 169.7 ± 7.1 | ||||||
| BMI (kg·m–2) | 33.8 ± 1.9 | 29.8 ± 5.0 | ||||||
| BSA (m2) | 1.97 ± 0.03 | 1.99 ± 0.18 | ||||||
| Weight (kg) | 87.3 ± 3.9 | 87. ± 14.8 | 87.6 ± 4.8 | 87.7 ± 4.6 | 84.3 ± 14.6 | 85.4 ± 13.5 | 85.9 ± 13.6 | 84.7 ± 13.2 |
| S[E2] (pg·mL–1) | 34.1 ± 18.7 | 26.3 ± 22.5 | 173.5 ± 118.3* | 163.0 ± 66.2* | 48.7 ± 31.9 | 29.9 ± 35.3 | 232.0 ± 188.5* | 178.5 ± 170.5* |
| S[P4] (ng·mL–1) | 1.1 ± 0.8 | 0.6 ± 0.1** | 0.6 ± 0.1** | 0.6 ± 0.2** | 1.0 ± 0.4 | 0.9 ± 0.2 | 1.1 ± 0.7 | 0.8 ± 0.2 |
| Total S[T] (ng·dL–1) | 0.3 ± 0.2 | 0.2 ± 0.4 | 0.2 ± 0.4 | 1.4 ± 0.6* | 0.4 ± 0.1 | 0.3 ± 0.9 | 0.3 ± 0.4 | 1.2 ± 0.7* |
| Free S[T] (ng·dL–1) | 0.03 ± 0.09 | 0.02 ± 0.03 | 0.6 ± 0.02 | 0.36 ± 0.18* | 0.12 ± 0.04 | 0.05 ± 0.04 | 0.06 ± 0.03 | 0.26 ± 0.16* |
| P[ET-1] (fmol·mL–1) | 2.01 ± 0.71 | 1.45 ± 2.6 | 3.68 ± 0.90* | 3.25 ± 1.78 | 3.58 ± 2.07 | 7.10 ± 2.48*,** | ||
BSA (m2) = ([height (cm) × weight (kg)]/3600)1/2.
*
Different from GnRH antagonist within the group, P < 0.05.
**
Different from baseline within the group, P < 0.05.
**
Different from control, P < 0.05.